Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report

Johnson & Johnson (NYSE:JNJ) is reportedly in discussions to acquire Protagonist Therapeutics (NASDAQ:PTGX).Citing people close to the talks, the Wall Street Journal reported that the deal is not guaranteed, and the terms have yet to be finalized.Year to date, Protagonist Therapeutics' stock has gained around 132%, as per data from Benzinga Pro.Partnership May Evolve Into Full OwnershipJohnson & Johnson and Protagonist already share a collaboration to develop an oral therapy targeting plaque psoriasis and u ...